About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Leap Therapeutics image

Leap Therapeutics

Rank#9053
Market Cap116.14M
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Historyarrow

Leap Therapeutics, Inc. was founded in 2012 to develop innovative therapies to treat some of the toughest cancers. After assembling a world-class life sciences team with deep experience in oncology drug development, the Company has since acquired, developed or in-licensed several clinically and commercially durable compounds, as well as recruited a number of strategic and corporate partners to help bring these treatments to market.

Missionarrow
Our mission is to develop and commercialize targeted and immuno-oncology therapies to improve the lives of cancer patients.
Visionarrow
Our vision is to become a trusted and respected leader in the targeted and immuno-oncology markets with a unique portfolio of innovative treatments and a competitive consumer-oriented commercial strategy.
Referencesarrow

https://in.investing.com/equities/leap-therapeutics-inc

https://finance.yahoo.com/quote/LPTX/profile?p=LPTX

https://www.comparably.com/companies/leap/mission

https://www.crunchbase.com/organization/leap-therapeutics

https://companiesmarketcap.com/

https://www.leaptx.com

Share

Leadership team
M
Mr. Douglas E. Onsi J.D. (CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director)
M
Mr. Augustine J. Lawlor (Chief Operating Officer)
D
Dr. Cynthia A. Sirard (Chief Medical Officer)
Products / Services
Biotechnology, Life Science
Address
Cambridge, Massachusetts, United States
Established
2011-01-01
Company Registration
SEC CIK number: 0001509745
Traded as
LPTX
Website
https://www.leaptx.com
Social Media
linkedinfacebookx
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo